Author/Authors :
Bozorgmehr, Rama Clinical Research Development Unit - Shohada-e Tajrish Hospital - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Amiri, Farbod Men’s Health and Reproductive Health Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Hosein Zadeh, Mohammad Department of internal medicine - Shohada-e Tajrish Hospital - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Ghorbani, Fariba Tracheal Diseases Research Center - National Research Institute of Tuberculosis and Lung Diseases - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Khameneh Bagheri, Arash Department of Radiology - Shohada-e Tajrish Hospital - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Yazdi, Esmat Department of internal medicine - Shohada-e Tajrish Hospital - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Nekooghadam, Mojtaba Department of internal medicine - Shohada-e Tajrish Hospital - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Pourdowlat, Guitti Chronic Respiratory Diseases Research Center - National Research Institute of Tuberculosis and Lung Disease (NRITLD) - Shahid Beheshti University of Medical Sciences, Tehran, Iran , Fatemi, Alireza Men’s Health and Reproductive Health Research Center - Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract :
Introduction: Efforts to control the COVID-19 pandemic are still on. This study aimed to evaluate the effect of
sofosbuvir on length of hospital stay and complications in COVID-19 cases with moderate severity. Methods:
This randomized clinical trial was done on moderate COVID-19 cases, who were admitted to Shohadaye Tajrish
Hospital, Tehran, Iran, from 4/2021 to 9/2021. Eligible patients were randomly allocated into two groups of
intervention (sofosbuvir) and control, and their outcomes were compared regarding the length of hospital stay
and complications. Results: 100 COVID-19 cases were randomly divided into two groups of 50 patients, as
the intervention and control groups. The mean age of patients was 50.56 ± 12.23 and 57.1±14.1 years in the
intervention and control groups, respectively (p = 0.02). The two groups were similar regarding distribution of
gender (p = 0.15), underlying diseases (p = 0.08), the severity of COVID-19 (p = 0.80) at the time of admission,
signs and symptoms (p > 0.05), and essential laboratory profile (p > 0.05). The length of hospital stay in the
control and intervention groups was 7.7 ± 4.09 days and 4.7±1.6 days, respectively (p = 0.02). None of our patients
needed ICU or mechanical ventilation. Conclusion: Sofosbuvir may decrease the length of hospital stay of
COVID-19 cases with moderate severity, without a significant effect on the rate of intensive care unit (ICU) need
and mortality.
Keywords :
SARS-CoV-2 , Treatment Outcome , Sofosbuvir , Duration of Therapy
